论文部分内容阅读
目的观察舒利迭(50/500μg)在慢性阻塞性肺疾病(COPD)缓解期中的疗效。方法确诊的中重度COPD患者46例,随机分为治疗组和对照组。对照组给予茶碱缓释片0.2,bid,万托林2～3喷,tid;治疗组给予吸入舒利迭(50/500μg),bid。结果治疗组在观察期间临床症状、肺功能较对照组明显改善、急性发作次数明显低于对照组。结论在中重度COPD缓解期中应用舒利迭能提高患者肺功能,明显改善症状,减少急性发作。
Objective To observe the efficacy of seretide (50 / 500μg) in the remission of chronic obstructive pulmonary disease (COPD). Methods Forty-six patients with moderate-to-severe COPD diagnosed were randomly divided into treatment group and control group. The control group was given theophylline sustained-release tablets 0.2, bid, wantroplin 2 to 3 spray, tid; the treatment group was given inhaled seretide (50 / 500μg) bid. Results During the observation period, the clinical symptoms and pulmonary function of the treatment group were significantly improved compared with the control group. The number of acute attacks was significantly lower than that of the control group. Conclusion The application of seretide in moderate to severe COPD remission can improve lung function, significantly improve symptoms and reduce acute attack.